Latest Insider Transactions at Oak Street Health, Inc. (OSH)
This section provides a real-time view of insider transactions for Oak Street Health, Inc. (OSH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Oak Street Health, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Oak Street Health, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 02
2023
|
Newlight Partners LP Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
32,550,265
-100.0%
|
$1,269,460,335
$39.0 P/Share
|
|
May 02
2023
|
Timothy M Cook Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
84,482
-100.0%
|
$3,294,798
$39.0 P/Share
|
|
May 02
2023
|
Timothy M Cook Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,456,206
-100.0%
|
$56,792,034
$39.0 P/Share
|
|
May 02
2023
|
Robert Guenthner Chief Legal Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
489,270
-100.0%
|
$19,081,530
$39.0 P/Share
|
|
May 02
2023
|
Regina M. Benjamin Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
23,881
-100.0%
|
$931,359
$39.0 P/Share
|
|
May 02
2023
|
Mohit Kaushal Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
215,224
-100.0%
|
$8,393,736
$39.0 P/Share
|
|
May 02
2023
|
Paul B. K. Kusserow Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
480,013
-100.0%
|
$18,720,507
$39.0 P/Share
|
|
May 02
2023
|
Michael T Pykosz Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,040,273
-100.0%
|
$40,570,647
$39.0 P/Share
|
|
May 02
2023
|
Michael T Pykosz Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
6,126,706
-100.0%
|
$238,941,534
$39.0 P/Share
|
|
May 02
2023
|
Kim Keck Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
94,960
-100.0%
|
$3,703,440
$39.0 P/Share
|
|
May 02
2023
|
Julie D Klapstein Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
31,684
-100.0%
|
$1,235,676
$39.0 P/Share
|
|
May 02
2023
|
Griffin Myers Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
4,845,659
-100.0%
|
$188,980,701
$39.0 P/Share
|
|
May 02
2023
|
Griffin Myers Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
8,511
-100.0%
|
$331,929
$39.0 P/Share
|
|
May 02
2023
|
Geoffrey M Price Chief Innovation Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,080,970
-100.0%
|
$42,157,830
$39.0 P/Share
|
|
May 02
2023
|
Geoffrey M Price Chief Innovation Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,879,525
-100.0%
|
$151,301,475
$39.0 P/Share
|
|
May 02
2023
|
Brian Clem Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
569,826
-100.0%
|
$22,223,214
$39.0 P/Share
|
|
May 02
2023
|
Cheryl Dorsey Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
29,484
-100.0%
|
$1,149,876
$39.0 P/Share
|
|
May 02
2023
|
General Atlantic LLC Director |
SELL
Other acquisition or disposition
|
Indirect |
61,384,475
-100.0%
|
$2,393,994,525
$39.0 P/Share
|
|
Apr 26
2023
|
Newlight Partners LP Director |
SELL
Bona fide gift
|
Indirect |
80,000
-100.0%
|
-
|
|
Apr 23
2023
|
Paul B. K. Kusserow Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,140
+1.06%
|
-
|
|
Apr 23
2023
|
Julie D Klapstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,140
+9.17%
|
-
|
|
Apr 23
2023
|
Kim Keck Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,140
+6.48%
|
-
|
|
Apr 23
2023
|
Cheryl Dorsey Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,140
+14.85%
|
-
|
|
Apr 23
2023
|
Mohit Kaushal Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,140
+2.33%
|
-
|
|
Apr 23
2023
|
Regina M. Benjamin Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,140
+17.72%
|
-
|
|
Apr 20
2023
|
Geoffrey M Price Chief Innovation Officer |
BUY
Other acquisition or disposition
|
Indirect |
1,080,970
+50.0%
|
-
|
|
Apr 20
2023
|
Geoffrey M Price Chief Innovation Officer |
SELL
Bona fide gift
|
Indirect |
1,080,970
-100.0%
|
-
|
|
Apr 18
2023
|
Geoffrey M Price Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
50,000
-1.27%
|
$1,900,000
$38.88 P/Share
|
|
Apr 18
2023
|
Geoffrey M Price Chief Innovation Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+1.26%
|
$1,050,000
$21.0 P/Share
|
|
Apr 10
2023
|
Timothy M Cook Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,978
-0.41%
|
$227,164
$38.82 P/Share
|
|
Apr 10
2023
|
Geoffrey M Price Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
4,517
-0.12%
|
$171,646
$38.82 P/Share
|
|
Apr 10
2023
|
Robert Guenthner Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,169
-0.64%
|
$120,422
$38.82 P/Share
|
|
Apr 04
2023
|
Geoffrey M Price Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
50,000
-1.27%
|
$1,900,000
$38.8 P/Share
|
|
Apr 04
2023
|
Geoffrey M Price Chief Innovation Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+1.26%
|
$1,050,000
$21.0 P/Share
|
|
Mar 31
2023
|
Geoffrey M Price Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
450,000
-5.47%
|
$17,100,000
$38.69 P/Share
|
|
Mar 31
2023
|
Geoffrey M Price Chief Innovation Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
450,000
+5.19%
|
$9,450,000
$21.0 P/Share
|
|
Mar 24
2023
|
Michael T Pykosz Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
1,282,000
-16.86%
|
-
|
|
Mar 21
2023
|
Geoffrey M Price Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
50,000
-1.27%
|
$1,750,000
$35.73 P/Share
|
|
Mar 21
2023
|
Geoffrey M Price Chief Innovation Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+1.26%
|
$1,050,000
$21.0 P/Share
|
|
Mar 20
2023
|
Robert Guenthner Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
47,699
+8.83%
|
-
|
|
Mar 20
2023
|
Geoffrey M Price Chief Innovation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,611
+0.14%
|
-
|
|
Mar 20
2023
|
Timothy M Cook Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
92,592
+5.96%
|
-
|
|
Mar 20
2023
|
Brian Clem Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
101,010
+15.06%
|
-
|
|
Mar 20
2023
|
Griffin Myers Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,611
+39.73%
|
-
|
|
Mar 20
2023
|
Michael T Pykosz Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
196,408
+2.52%
|
-
|
|
Mar 17
2023
|
Geoffrey M Price Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
37,913
-0.97%
|
$1,326,955
$35.63 P/Share
|
|
Mar 17
2023
|
Geoffrey M Price Chief Innovation Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
37,913
+0.96%
|
$796,173
$21.0 P/Share
|
|
Mar 16
2023
|
Geoffrey M Price Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
79,858
-2.02%
|
$2,795,030
$35.62 P/Share
|
|
Mar 16
2023
|
Geoffrey M Price Chief Innovation Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
79,858
+1.98%
|
$1,677,018
$21.0 P/Share
|
|
Mar 15
2023
|
Geoffrey M Price Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
1,831
-0.05%
|
$64,085
$35.6 P/Share
|